Catalyst Pharmaceuticals, Inc. (CPRX)
CPRX moved a median of 0.00% 30 minutes after news, and -0.01% by the close. How CPRX actually reacts to news — the realized, point-in-time move the market made, measured across 441 labeled events over the last three years with zero look-ahead.
CPRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.08% | 56% | 402 |
| 30-min | 0.00% | 50% | 404 |
| 60-min | +0.02% | 51% | 404 |
| to close | -0.01% | 48% | 404 |
| Middle 50% of CPRX reactions | -0.63% to +0.66% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 441 |
Half of all Catalyst Pharmaceuticals, Inc. news events land between -0.63% and +0.66% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CPRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -0.02% | 47% | -0.06% |
| Analyst downgrades | 22 | 0.00% | 46% | -0.03% |
| Coverage initiations | 16 | +0.28% | 56% | +1.05% |
| Rating reiterations | 33 | +0.02% | 52% | -0.25% |
| Price-target raises | 10 | +0.08% | 50% | +0.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how CPRX ranks against every other measured name →
That’s how CPRX usually reacts — get an email when it moves on news →Email me when CPRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CPRX's baseline. Nothing else.
Recent CPRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G CATALYST PHARMACEUTICALS | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT CATALYST PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | Press release | GlobeNewswire | — | — | |
| Form 8-K CATALYST PHARMACEUTICALS For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM CATALYST PHARMACEUTICALS | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR CATALYST PHARMACEUTICALS | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS CATALYST PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Solaris Energy Infrastructure Set to Join S&P SmallCap 600 | Press release | PR Newswire | +0.02% | +0.00% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +0.00% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | -0.03% | |
| Form DEFA14A CATALYST PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.02% | -0.03% | |
| Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses | Press release | GlobeNewswire | +0.05% | +0.00% | |
| Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | -0.02% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.10% | |
| Form DEFM14A CATALYST PHARMACEUTICALS | SEC filing · Form DEFM14A | SEC EDGAR | +0.13% | +0.13% | |
| Form PREM14A CATALYST PHARMACEUTICALS For: May 28 | SEC filing · Form PREM14A | SEC EDGAR | +0.02% | -0.19% | |
| Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | +0.13% | |
| Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | -0.06% | |
| Form DEFA14A CATALYST PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.06% | |
| Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | -0.06% | |
| Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.06% | |
| Form 8-K CATALYST PHARMACEUTICALS For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.06% | |
| Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.08% | +0.00% | |
| Form DEFA14A CATALYST PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.08% | +0.00% | |
| Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease | Press release | GlobeNewswire | -0.14% | +0.08% | |
| Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. | Press release | GlobeNewswire | -0.14% | +0.08% | |
| Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast | Press release | GlobeNewswire | +0.05% | +0.06% | |
| CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.14% | +0.08% | |
| Form 8-K CATALYST PHARMACEUTICALS For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +0.08% | |
| Form DEFA14A CATALYST PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.14% | +0.08% | |
| Form 10-K/A CATALYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.85% | +2.13% | |
| Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 | Press release | GlobeNewswire | +1.86% | -0.54% | |
| Form 8-K/A CATALYST PHARMACEUTICALS For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | -1.06% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | -1.06% | |
| Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference | Press release | GlobeNewswire | -1.07% | +1.00% | |
| Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Press release | GlobeNewswire | -2.01% | +2.18% | |
| Form 10-K CATALYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.01% | +2.18% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | +2.18% | |
| Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.60% | +0.62% | |
| Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 | Press release | GlobeNewswire | -1.11% | -0.95% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | +2.56% | |
| Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies | Press release | GlobeNewswire | +0.31% | +0.13% | |
| The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) | Press release | GlobeNewswire | -0.56% | -0.96% | |
| Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.35% | +2.07% | |
| Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference | Press release | GlobeNewswire | +0.80% | +1.07% | |
| Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ | Press release | GlobeNewswire | +0.57% | -1.01% | |
| Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference | Press release | GlobeNewswire | +0.49% | +0.94% | |
| Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.03% | -7.04% | |
| Form 10-Q CATALYST PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.03% | -7.04% | |
| Form 8-K CATALYST PHARMACEUTICALS For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -7.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CPRX section they belong to.
Where else CPRX is measured.
CPRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 442 | -0.38% | 41% |
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Pacific Biosciences of California, Inc. (PACB) | 440 | -0.29% | 44% |
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Catalyst Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CPRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 441 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CPRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CPRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.